Marianne M Stanford

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7387611/publications.pdf

Version: 2024-02-01

43 papers	1,870 citations	249298 26 h-index	312153 41 g-index
43 all docs	43 docs citations	43 times ranked	2293 citing authors

#	Article	IF	Citations
1	The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase. Clinical Medicine Insights: Oncology, 2021, 15, 117955492199306.	0.6	2
2	Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in aÂHPV16 E7-expressing C3 tumour model. Scientific Reports, 2021, 11, 4502.	1.6	0
3	Generation of highly activated, antigen-specific tumor-infiltrating CD8 ⁺ T cells induced by a novel T cell-targeted immunotherapy. OncoImmunology, 2020, 9, 1782574.	2.1	2
4	Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy. OncoImmunology, 2020, 9, 1851539.	2.1	6
5	Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein. Human Vaccines and Immunotherapeutics, 2020, 16, 2007-2017.	1.4	7
6	Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics. Frontiers in Immunology, 2020, 11, 264.	2.2	22
7	Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge. Npj Vaccines, 2019, 4, 6.	2.9	12
8	A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study. Journal of Infectious Diseases, 2018, 218, 378-387.	1.9	39
9	Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform. Human Vaccines and Immunotherapeutics, 2018, 14, 59-66.	1.4	4
10	Using <scp>MRI</scp> cell tracking to monitor immune cell recruitment in response to a peptideâ€based cancer vaccine. Magnetic Resonance in Medicine, 2018, 80, 304-316.	1.9	30
11	Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control. Journal of Biomedical Science, 2018, 25, 7.	2.6	19
12	Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo. PLoS ONE, 2017, 12, e0180073.	1.1	22
13	Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. , 2016, 4, 68.		27
14	Using lymph node swelling as a potential biomarker for successful vaccination. Oncotarget, 2016, 7, 35655-35669.	0.8	11
15	Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15048.	1.8	7
16	Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. OncoImmunology, 2015, 4, e1026529.	2.1	79
17	Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. OncoImmunology, 2014, 3, e953407.	2.1	32
18	Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. Vaccine, 2014, 32, 6956-6962.	1.7	22

#	Article	IF	Citations
19	ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic. Molecular Therapy, 2012, 20, 1148-1157.	3.7	59
20	First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. Journal of Translational Medicine, 2012, 10, 156.	1.8	71
21	Targeting Tumor Vasculature With an Oncolytic Virus. Molecular Therapy, 2011, 19, 886-894.	3.7	149
22	Potent Oncolytic Activity of Raccoonpox Virus in the Absence of Natural Pathogenicity. Molecular Therapy, 2010, 18, 896-902.	3.7	27
23	Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing. Molecular Therapy, 2010, 18, 888-895.	3.7	109
24	Novel oncolytic viruses: Riding high on the next wave?. Cytokine and Growth Factor Reviews, 2010, 21, 177-183.	3.2	28
25	Intravenously Administered Alphavirus Vector VA7 Eradicates Orthotopic Human Glioma Xenografts in Nude Mice. PLoS ONE, 2010, 5, e8603.	1.1	51
26	Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors. PLoS ONE, 2010, 5, e14462.	1.1	63
27	Inhibition of Macrophage Activation by the Myxoma Virus M141 Protein (vCD200). Journal of Virology, 2009, 83, 9602-9607.	1.5	24
28	Myxoma Virus Is Oncolytic for Human Pancreatic Adenocarcinoma Cells. Annals of Surgical Oncology, 2008, 15, 2329-2335.	0.7	41
29	Myxoma Virus Oncolysis of Primary and Metastatic B16F10 Mouse Tumors In Vivo. Molecular Therapy, 2008, 16, 52-59.	3.7	69
30	Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?. Current Opinion in Molecular Therapeutics, 2008, 10, 32-7.	2.8	31
31	M-T5, the Ankyrin Repeat, Host Range Protein of Myxoma Virus, Activates Akt and Can Be Functionally Replaced by Cellular PIKE-A. Journal of Virology, 2007, 81, 2340-2348.	1.5	38
32	Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin. Cancer Research, 2007, 67, 8818-8827.	0.4	97
33	Oncolytic Virotherapy Synergism with Signaling Inhibitors: Rapamycin Increases Myxoma Virus Tropism for Human Tumor Cells. Journal of Virology, 2007, 81, 1251-1260.	1.5	72
34	Myxoma Virus Expressing Human Interleukin-12 Does Not Induce Myxomatosis in European Rabbits. Journal of Virology, 2007, 81, 12704-12708.	1.5	11
35	Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opinion on Biological Therapy, 2007, 7, 1415-1425.	1.4	73
36	Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. Journal of NeuroVirology, 2007, 13, 549-560.	1.0	31

#	Article	IF	Citations
37	Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunology and Cell Biology, 2007, 85, 93-102.	1.0	106
38	Tropism of Tanapox virus infection in primary human cells. Virology, 2007, 368, 32-40.	1.1	13
39	Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Veterinary Research, 2007, 38, 299-318.	1.1	77
40	Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4640-4645.	3.3	167
41	The â€˜supervirusâ€™? Lessons from IL-4-expressing poxviruses. Trends in Immunology, 2005, 26, 339-345.	2.9	26
42	The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo. Journal of Leukocyte Biology, 2003, 74, 791-799.	1.5	64
43	Delineation of Five Thyroglobulin T Cell Epitopes with Pathogenic Potential in Experimental Autoimmune Thyroiditis. Journal of Immunology, 2002, 169, 5332-5337.	0.4	30